Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why

Group 1 - Adma Biologics' stock closed at $19.44, reflecting a -0.26% change, underperforming compared to the S&P 500's 0.4% gain [1] - The stock has increased by 13.05% over the past month, contrasting with a 2.27% loss in the Medical sector and a 1.71% gain in the S&P 500 [1] - The upcoming EPS for Adma Biologics is projected at $0.13, indicating a 1200% increase year-over-year, with revenue estimates at $107.25 million, a 59.41% increase from the previous year [1] Group 2 - Recent analyst estimate changes for Adma Biologics suggest a positive outlook on the company's business and profitability [2] - The Zacks Rank for Adma Biologics is currently 2 (Buy), reflecting a strong potential for stock performance [2] - The Zacks Rank system has shown a historical average annual return of +25% for stocks rated 1 since 1988 [2] Group 3 - Adma Biologics has a Forward P/E ratio of 39.78, which is higher than the industry average of 21.99 [3] - The Medical - Biomedical and Genetics industry holds a Zacks Industry Rank of 84, placing it in the top 34% of over 250 industries [3] - The top 50% rated industries outperform the bottom half by a factor of 2 to 1, indicating strong industry performance potential [3]